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1. Introduction
Primary liver cancer (hepatocellular carcinoma, HCC) is
the ﬁfth most common cancer in men and the seventh
in women worldwide. 1 It rarely occurs before the age of
40 years and reaches its peak incidence at approximately
70 years of age. Major risk factors for HCC include:
infection with hepatitis B (HBV) or hepatitis C (HCV),
alcoholic liver disease, non-alcoholic fatty liver dis-
ease and less frequently, hereditary haemochromatosis,
primary biliary cirrhosis, alpha1-antitrypsin deﬁciency
or autoimmune hepatitis. Cirrhosis has the strongest
association with HCC and is the most common known
risk factor. HCC also occurs in non-cirrhotic livers in
10−15% of cases with viral- and alcoholic-associated
chronic liver diseases and in 40−60% of cases with non-
alcoholic steatohepatitis (NASH). 2,3
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2. Barcelona Clinic Liver Cancer (BCLC) treatment
algorithm
The Barcelona Clinic Liver Cancer (BCLC) staging system
has been accepted worldwide in clinical practice and for
many clinical trials. The American Association for the
Study of Liver Diseases recommendations regarding liver
transplantation (based on the Milan criteria) have not
been changed in the 2011 update 4 because there are no
new data which suggest any beneﬁt in expanding these
patient selection criteria. The utility of portal pressure
measurement to deﬁne optimal candidates for major
resection has been validated. Resection should therefore
be the ﬁrst-line approach in patients with normal
portal pressure and bilirubin, even though studies
of radiofrequency ablation (RFA) have demonstrated
complete ablation of lesions <2 cm, 5 with low local
recurrence rates of <1%.
2.1. Transarterial chemoembolisation
The candidates for transarterial chemoembolisation
(or TACE) include those with Child–Pugh A or B liver
function and intermediate (BCLC) stage B HCC, includ-
ing patients with unresectable multinodular or large
tumours. However, a greater degree of standardisation
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Fig. 1 – Future multidisciplinary approaches for HCC treatment.
of TACE techniques is needed. Recently, a new form
of TACE (drug-eluting bead [DEB] with doxorubicin)
has been developed to enhance tumour drug delivery
and reduce systemic availability of conventional TACE.
Particularly for patients with more advanced HCC and
Child–Pugh B, DEB is associated with improvements
in 6-month tumour response (as measured by EASL)
compared with conventional TACE. 6
Patients who have either failed TACE or present with
more advanced HCC may beneﬁt from sorafenib, a
multikinase inhibitor. Sorafenib has been approved as
the ﬁrst-line treatment in patients with advanced HCC
based on the results from the SHARP study. 7 Recent
studies have also assessed the beneﬁt of sorafenib
as an adjuvant treatment or in combination with
other techniques, such as TACE, to improve efﬁcacy
(Fig. 1). This has dramatically heightened interest in
the development of new treatments for HCC amongst
previously reticent drug companies. There are now more
than 50 phase I−III clinical trials evaluating targeted
chemotherapies. Together, these studies might change
the management of HCC and provide new combination
therapies for intermediate as well as advanced HCC.
2.2. Selective internal radiation therapy
The use of selective internal radiation therapy (SIRT),
also known as radioembolisation, in HCC is currently
supported by retrospective or non-controlled studies. 8,9
These studies have shown that the median survivals
with SIRT are similar to TACE and sorafenib, in BCLC B
and BCLC C patients, respectively. Relevant clinical
trials (SIRTACE, SORAMIC, SARAH) are now ongoing to
determine the appropriate place of SIRT compared with
TACE and targeted therapies in the treatment of HCC. 10
A radiographic objective response to locoregional
therapies (TACE or SIRT) using WHO or EASL criteria
has recently been shown to predict survival in patients
with Child–Pugh B7 or lower. 11 However, with low
response rates to targeted therapies (only 2% of partial
response according to RECIST criteria in the SHARP
study 5), anatomical imaging using the RECIST criteria
has become inappropriate. Instead, magnetic resonance
imaging (MRI) diffusion and computed tomography (CT)
perfusion have enabled more accurate analysis of the
vascular and interstitial compartments of the tumour
after antiangiogenic therapy. In addition, the concept
of viable tumour (i.e. mRECIST criteria) deﬁned as an
uptake of contrast agent in the arterial phase of dynamic
CT or MRI and the tumour density variations using CT 12
might also improve the analysis of tumour response with
targeted therapies.
3. Biomarkers
Finally, biomarkers have been characterised recently and
provide additional tools in the evaluation of patients
and the tailoring of treatment. Such surrogates may be
of major interest to track the effect of antiangiogenic
therapies, particularly in the case of stable disease:
antiangiogenic agents may improve survival by slowing
down tumour progression, without any obvious signs
of tumor shrinkage or regression. 7,13 The identiﬁcation
of oncogenes that mediate tumour progression and
trials that monitor their products as biomarkers, might
lead to personalised therapies with optimal activity and
cost beneﬁt. 14
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